MJ Business Attorneys

JUNE 29, 2018

Epidiolex is the first drug the FDA has approved that contains a substance derived from marijuana, and it is also the first drug approved by the FDA to be used to treat patients with Dravet syndrome. Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. In the recent case Hemp Industries Associations v.

DEA 113

DEA CBD Pharmaceutical Research and Development 113

Cannabis Law Report

DECEMBER 7, 2021

On November 16, 2021, the Drug Enforcement Agency (DEA) issued an advance notice of proposed rulemaking , exploring whether or not to create new federal regulations governing the practice of telepharmacy. The DEA’s notice provides the industry with an opportunity to provide insight and feedback that may help shape the new regulations.

DEA 52

DEA Patients Therapy Access 52

Cannabis Law Report

NOVEMBER 2, 2022

Drug Enforcement Administration and the legal team representing terminally ill patients petitioning for access to psilocybin-assisted therapy. In late September, the DEA denied an official petition requesting that the agency look into rescheduling psilocybin from Schedule I to Schedule II.

Microdosing 52

Microdosing DEA Therapy Access 52

Cannabis Law Report

MAY 10, 2022

Activists staged a demonstration outside of the Drug Enforcement Administration (DEA) headquarters in Virginia on Monday, demanding that the agency allow terminally ill patients to access psilocybin therapy. Patients, veterans and key advocates participated in the demonstration. Marijuana Moment reports.

DEA 52

DEA Therapy Access Patients 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. . Most recently the FDA awarded MMJ International Holdings ?

DEA 66

DEA Clinical Trials THC Research and Development 66

Veriheal

APRIL 11, 2022

You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Canna Law Blog

MARCH 4, 2020

In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care. The FDA doesn’t have any regulations on point for the control and oversight of ketamine clinics when it comes to infusion therapy and the states don’t really either.

Therapy 89

Therapy Legalization Chronic Pain DEA 89

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. DEA and the Controlled Substances Act.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

APRIL 21, 2022

Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public . 30,000 patient doses) of MDMA in a four-step process beginning with a non-controlled starting material. The safety and efficacy of MDMA-assisted therapy is currently under investigation.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

JULY 9, 2021

The use of psychedelic substances to treat mental illness and physical disorders is known as “psychedelic therapy.” In a typical scenario, psychedelic substances would be used in conjunction with psychotherapy sessions to treat disorders for which other medicinal therapies have failed. Psychedelic therapy is not a fringe phenomenon.

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

JULY 1, 2021

In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency recognized psilocybin as a breakthrough therapy for treatment-resistant depression. Mason Marks: The project’s goal is to promote safety, innovation, equity, and accessibility in emerging psychedelics industries.

Law 105

Law Research and Development Therapy DEA 105

Canna Law Blog

MARCH 4, 2020

In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care. The FDA doesn’t have any regulations on point for the control and oversight of ketamine clinics when it comes to infusion therapy and the states don’t really either.

Legalization 52

Legalization Therapy Chronic Pain DEA 52

SpeedWeed

MAY 15, 2021

A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. For this study, researchers recruited 90 patients suffering from severe, chronic PTSD. Image via. This promising new study is helmed by Rick Doblin, Ph.D.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

MedicalJane

JUNE 29, 2018

The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome. The Next Move Is On The DEA.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Veriheal

NOVEMBER 11, 2023

According to the United States Drug Enforcement Administration (DEA), Schedule One drugs are “drugs with no currently accepted medical use and a high potential for abuse.” 5520), and the Veterans Equal Access Act (H.R. However, it is clear that there is momentum to give veterans access to cannabis. Yes, it has.

Law 62

Law Chronic Pain Conditions Legislation 62

SpeedWeed

AUGUST 16, 2021

And we’re gonna have to change therapies to try to win this battle. Lepp was one of the industry’s greatest advocates, leaving his mark as one of many who suffered in prison as a result of trying to cultivate medical cannabis and help patients get access. I have cancer of the bone now. We will not take money for marijuana.

DEA 52

DEA Patients Therapy Cannabis 52

Canna Care Docs

SEPTEMBER 26, 2019

Powered by Sail, we are on a mission to solve the issue of cannabis access for patients. We’re passionate about improving our patient’s quality of life and bringing cannabis into mainstream healthcare. Evaluate patient for verification of a qualifying condition. About Canna Care Docs…. Why Work for CannaCareDocs?

History 40

History DEA Therapy Patients 40

Cannabis Law Report

MAY 31, 2022

Two approaches apply to commercial operations—the traditional medical path and the emerging non-medical state-regulated path, while the other two paths are better seen as non-commercial—underground therapy and religious use. The first path, that of traditional medicine, currently offers patients limited options. Breakthrough Therapy.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

APRIL 13, 2022

North American Industry Leader in Psychedelic Therapy and Research. Shared mission of responsibly reintroducing psychedelic therapy to mental healthcare. “Since Numinus began, we have always strived to be the most trusted, evidence-based leader in psychedelic-assisted therapy and medicine. NEWS PROVIDED BY. ” Mr. .

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

FEBRUARY 28, 2022

Moreover, because Indigenous communities pioneered many aspects of modern psychedelic therapies, their patenting by Western corporations may promote biopiracy, the exploitation of Indigenous knowledge without compensation. MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study , 27 NATURE MED.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

SpeedWeed

JULY 22, 2021

The attorney general can also choose to waive that right and let the DEA review the petition instead. . Each day cannabis remains overly scheduled, patients and researchers across the United States continue to lose access to life-saving therapies and data.”. And Joyce and Young’s cannabis activism doesn’t end there.

DEA 52

DEA Therapy Cannabis Patients 52

Cannabis Law Report

JULY 30, 2019

The informed patients, cannabis industry employees, and clinicians find it equally difficult to keep updated on Florida’s latest medical marijuana program news and changes. . In light of all this state cannabis information overload, what are some of the reasons a patient ultimately chooses a qualified personal cannabis physician? .

Marijuana 45

Marijuana Patients Research and Development Programs 45

Sensi Seeds

NOVEMBER 28, 2018

Food and Drug Administration (FDA) earlier this year, and convince the DEA to reclassify CBD from a Schedule I (most restrictive category) to a Schedule V drug (least restrictive category.) As a result, GW’s latest CBD product, EPIDIOLEX ® was entered into the Spanish pharmacopeia over the summer.

CBD 71

CBD Seed-To-Sale Food Research and Development 71

The Cannigma

FEBRUARY 16, 2022

So, with that, we should get into it, but don’t forget to check out our segment with Americans for Safe Access. We always have a nice little tidbit when we’re all about advocacy and access to cannabis for all. Codi Peterson here with our regularly scheduled segment with Americans for Safe Access. How are you?

Trichome 73

Trichome Wellness and Beauty Cannabinoids Cannabis 73